For citations:
Lozhkina N.G., Dobrovolskaya N.P., Artemenko S.N., Shipunov M.V., Sharonin A.D., Koltyugina V.A., Timofeev V.S., Voyevoda M.I. Efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk. Russian Journal of Cardiology. 2025;30(3):5869. (In Russ.) https://doi.org/10.15829/1560-4071-2025-5869. EDN: RZWJCG